FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
07/21/2026
Back to search
Official data from USPTO
WHY WAIT!
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
34
Latest update
07/21/2026
Trademark type
Combined
Nice classes
5, 32
Filing date
06/12/2024
Registration date
04/21/2026
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
04/21/2026
Last transaction
07/21/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
5
Owner type
99
Owner location
AU
Examiner
FOSDICK, GEOFFREY A
Law office
M20
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of the wording "WHY WAIT!" in stylized font.
Holders and representatives
Holders
Clinically Approved Holdings Pty Ltd
Representatives
Amy C. Ziegler Greer, Burns & Crain Ltd.
Technical classification
Nice Classes
Class 5Class 32
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Vitamins; mineral supplements; nutritional supplements; multivitamin preparations; pharmaceutical preparations containing vitamins for the treatment of cardiovascular diseasespainskin conditionscold and flujoint and muscle diseases; pharmaceutical preparations containing omega 3 for the treatment of cardiovascular diseasespainskin conditionscold and flujoint and muscle diseases; pharmaceutical preparations for metabolic support; pharmaceutical preparations for the improvement of brain healthimmunitysleepmoodgut healthwomen's health; pharmaceutical preparations containing vitamins for pregnancy; vitamin supplements; vitamin fortified beverages for medical use; vitamin preparations; medicines for treatment of heart diseases; pharmaceutical products for combating heart diseases; pharmaceutical tablets for the treatment of cardiovascular diseasespainskin conditionscold and flujoint and muscle diseases; pharmaceutical tablets containing omega 3 for the treatment of cardiovascular diseasespainskin conditionscold and flujoint and muscle diseases; pharmaceutical tablets for metabolic support; pharmaceutical tablets for the improvement of brain healthimmunitysleepmoodgut healthwomen's health; pharmaceutical tablets containing vitamins for pregnancy; anti-inflammatories; vitamin mineral and herbal preparations in tablet and powder form for medical use; dietary nutritional supplements; dietary supplements; dietetic drinks adapted for medical purposes; dietetic food supplements adapted for medical purposes; effervescent vitamin tablets; herbal extractsother than essential oilsfor medical purposes; food supplementsantioxidantsomega 3; dietary food supplements; medicated food supplements; nutritionally fortified beverages adapted for medical purposes; therapeutic agents for weight control and appetite suppression; vitamin tablets; dietary supplements in powder form; medicinal drinks; dietary supplements in capsule form; dietary supplements in liquid capsule form; gummy vitamins; medicines and chemical compounds for the treatment and support of blood circulation; pharmaceutical preparationsmedicines and chemical compounds for the treatment of cardiovascular diseases; pharmaceutical preparationsmedicines and chemical compounds for the health of blood cells and production of blood lipidspharmaceutical preparationsmedicines and chemical compounds for treatment of cells exposed to oxidants; pharmaceutical preparationsmedicines and chemical compounds to treat blood disorders; pharmaceutical preparationsmedicines and chemical compounds to treat cardiovascular diseases and for cardiovascular health; chemical preparations for the treatment of cognitive decline; chemical preparations for the treatment of anxiety; chemical preparations for depression; pharmaceutical preparations for the treatment of alzheimers disease; pharmaceutical preparations for the treatment and management of coronavirus disease; pharmaceutical preparations for strengthening human immune responses; pharmaceutical preparations for treatment of influenza variations; pharmaceutical preparations for sleep support; mineral food supplements; analgesics and analgesic preparations; analgesic preparationsmedicines and chemical compounds to supportassistrelieve and treat blood circulationartery wellness and strong cardiovascular systemheart diseasehealthy red blood cell production and healthy blood lipidscell energy and to protect cells from oxidative damage and calcium absorption and to maintain healthy blood glucosein liquidtabletcapsulepowdertea and gummy form; analgesic preparationsmedicines and chemical compounds to supportassistrelieve and treat excessive immune response in relation to coronavirus diseasedelivered in liquidtabletcapsulepowdertea and gummy form; analgesic preparationsmedicines and chemical compounds to treat for excessive immune response in humans with influenzain liquidtabletcapsulepowdertea and gummy form; analgesic preparationsmedicines and chemical compounds to supportassistrelieve and treat Alzheimer's diseaseage related mental declineanxiety and depressionbrain fogstressADHDslow memory and cognitive decline; analgesic preparationsmedicines and chemical compounds to improve brain functionbrain health during pregnancy and early childhood in liquidtabletcapsulepowdertea and gummy form; analgesic preparationsmedicines and chemical compounds to supportassistrelieve and treat joint painjoint diseasearthritismild joint achesto maintain joint mobility and/or flexibilityhealthy joint cartilage growth and/or joint healthin liquidtabletcapsulepowdertea and gummy form; analgesic preparationsmedicines and chemical compounds to support and assist sleep qualitysleep patternsthe time required to fall asleepin liquidtabletcapsulepowdertea and gummy form; analgesic preparationsmedicines and chemical compounds to increase calmnesssupport healthy stress response in the human bodyreduce stress and anxietyrelieve symptoms of stressanxiety or nervous tensionin liquidtabletcapsulepowdertea and gummy form; analgesic preparationsmedicines and chemical compounds for the relief and treatment of paininflammationdiscomfort and swelling in connection with or related to any body component includingwithout limitationmuscular aches and painsbackacheheadachemigraine headachetension headachesinus paintoothachedental painperiod painsore throattennis elbowrheumatic painaches and pains associated with colds and flufemale period painpain and sleeppain in connection with manual and/or physical labourand/or pain in connection with the recovery of injuryharmdecline and damage to any body componentdelivered in liquidtabletcapsulepowdertea and gummy form; analgesicsmedicines and chemical compounds to support and treat eye visionage-related eye diseaseseye healtheye conditions including dry eyeaged-related Macular Degeneration and/or cataractsin liquidtabletcapsulepowdertea and gummy form; analgesicsmedicines and chemical compounds for the treatment of the health and quality of skincell growth and renewalskin damageskin wrinkle depthskin hydrationskin appearancein liquidtabletcapsulepowdertea and gummy form; analgesicsmedicines and chemical compounds for the treatment of heart healthbrain healtheye healthmuscle healthjoint healthcolonprostate and breast cancersmetabolic syndromein liquidtabletcapsulepowdertea and gummy form
Class 32
Non-alcoholic beveragescarbonated beverages; concentrates and powders used in the preparation of soft drinks; drinking water
Publications
History of USPTO decisions and trademark events.
34 publications found
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
04/21/2026
R.PR
REGISTERED-PRINCIPAL REGISTER
04/21/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/03/2026
PUBO
PUBLISHED FOR OPPOSITION
03/03/2026
GPNX
NOTIFICATION PROCESSED BY IB
02/26/2026
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/25/2026
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
02/12/2026
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
02/11/2026
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
02/10/2026
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/03/2026
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/03/2026
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/03/2026
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
02/03/2026
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
01/27/2026
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
01/27/2026
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
09/05/2025
GNFR
FINAL REFUSAL E-MAILED
09/05/2025
CNFR
FINAL REFUSAL WRITTEN
09/05/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/02/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/02/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/02/2025
RFNT
REFUSAL PROCESSED BY IB
03/22/2025
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
03/04/2025
RFRR
REFUSAL PROCESSED BY MPU
03/04/2025
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
01/16/2025
CNRT
NON-FINAL ACTION WRITTEN
01/15/2025
RFWR
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
01/15/2025
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
12/20/2024
CNRT
NON-FINAL ACTION WRITTEN
12/19/2024
DOCK
ASSIGNED TO EXAMINER
12/18/2024
MAFR
APPLICATION FILING RECEIPT MAILED
08/30/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/30/2024
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
08/29/2024
Continuous trademark protection
Get notified about every new filing that threatens WHY WAIT! or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.